THROMBOGENICS corporate highlights 2013
“Not having to undergo surgery makes a huge difference for VMT patients” Clara Eaglen of the Royal National Institute of Blind People stresses the impact of JETREA® on patients’ lives The Royal National Institute of Blind People (RNIB), the leading charity for people with sight loss in the UK, asked several patients with symptomatic VMT and/or macular hole how their disease was treated before JETREA® was launched and what the impact was on their lives. “They all agreed that the worst parts of their treatment were the ‘watch and wait’ procedure and having to posture for several days after a vitrectomy”, says Clara Eaglen, Policy and Campaigns manager at the RNIB. “JETREA® can resolve both those issues.” For a selection of approved new medicines by the EMA, the National Institute for Health and Care Excellence (NICE) in the United Kingdom investigates the cost-effectiveness of the product and whether it can be used and reimbursed in the National Health Service of England and Wales. “In the appraisal process of new treatments, NICE seeks opinions from clinicians, health economists and patients. With the RNIB, we make sure that NICE understands the importance of certain new drugs for those patients”, clarifies Clara Eaglen. “It is crucial that patients’ voices are heard during
33